JP2022523442A5 - - Google Patents

Info

Publication number
JP2022523442A5
JP2022523442A5 JP2021553382A JP2021553382A JP2022523442A5 JP 2022523442 A5 JP2022523442 A5 JP 2022523442A5 JP 2021553382 A JP2021553382 A JP 2021553382A JP 2021553382 A JP2021553382 A JP 2021553382A JP 2022523442 A5 JP2022523442 A5 JP 2022523442A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
bispecific antibody
seq
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021553382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523442A (ja
JP7566766B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000342 external-priority patent/WO2020183245A2/en
Publication of JP2022523442A publication Critical patent/JP2022523442A/ja
Publication of JP2022523442A5 publication Critical patent/JP2022523442A5/ja
Priority to JP2024135000A priority Critical patent/JP2024170426A/ja
Application granted granted Critical
Publication of JP7566766B2 publication Critical patent/JP7566766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021553382A 2019-03-11 2020-03-11 抗Vβ17/抗CD123二重特異性抗体 Active JP7566766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135000A JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
US62/816,464 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135000A Division JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2022523442A JP2022523442A (ja) 2022-04-22
JP2022523442A5 true JP2022523442A5 (https=) 2023-03-17
JP7566766B2 JP7566766B2 (ja) 2024-10-15

Family

ID=71670296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553382A Active JP7566766B2 (ja) 2019-03-11 2020-03-11 抗Vβ17/抗CD123二重特異性抗体
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Country Status (12)

Country Link
US (2) US12264197B2 (https=)
EP (1) EP3937977A2 (https=)
JP (2) JP7566766B2 (https=)
KR (1) KR20210138033A (https=)
CN (2) CN119954959A (https=)
AU (1) AU2020235475A1 (https=)
BR (1) BR112021017801A2 (https=)
CA (1) CA3132916A1 (https=)
IL (1) IL286147A (https=)
MA (1) MA55305A (https=)
MX (1) MX2021010857A (https=)
WO (1) WO2020183245A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3190987A1 (en) * 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
TW202227495A (zh) * 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
TW202406932A (zh) * 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2024543019A (ja) * 2021-11-01 2024-11-19 ヤンセン バイオテツク,インコーポレーテツド β鎖媒介免疫を調節するための組成物及び方法
WO2023152633A1 (en) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
EP4662239A1 (en) * 2023-02-09 2025-12-17 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
FR2681875A1 (fr) 1991-09-26 1993-04-02 Immunotech Sa Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US6084087A (en) * 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス, インコーポレイテッド 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
MA40609B1 (fr) * 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
EP3215538A4 (en) 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
CA2979759C (en) 2015-04-16 2023-08-08 Eisai R&D Management Co., Ltd. Anti-human notch4 antibody
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
WO2018112407A1 (en) * 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
KR20200041834A (ko) * 2017-06-01 2020-04-22 젠코어 인코포레이티드 Cd123 및 cd3에 결합하는 이중특이성 항체
JP7404252B2 (ja) 2017-11-08 2023-12-25 ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド 生体分子のコンジュゲートおよびその使用
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2595980B (en) 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
EP3986936A4 (en) 2019-06-21 2023-03-15 Single Cell Technology, Inc. ANTI-TIGIT ANTIBODIES
AU2020359070A1 (en) 2019-10-03 2022-04-21 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
AU2021225870A1 (en) 2020-02-27 2022-10-20 Janssen Biotech, Inc. Materials and methods for modulating an immune response
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
US20220089737A1 (en) 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof

Similar Documents

Publication Publication Date Title
JP2022523442A5 (https=)
JP2022177090A5 (https=)
JP2024109678A5 (https=)
JP2022533538A5 (https=)
JP2022106952A5 (https=)
JP2021516057A5 (https=)
JP2020534830A5 (https=)
JP2021501744A5 (https=)
CN112135626A (zh) 抗tigit抗体及其用途
JP2020537520A5 (https=)
IL309975A (en) Antibodies against C5 and their uses
JP2010246565A5 (https=)
JP2023093753A5 (https=)
HRP20130883T4 (hr) Međuvrsno specifična cd3-epsilon-vežuća domena
JP2013520984A5 (https=)
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
NZ608660A (en) Anti-cd48 antibodies and uses thereof
JP2011510654A5 (https=)
JP2024540148A5 (https=)
JP2024531409A5 (https=)
JP2021500916A5 (https=)
JP2025067915A5 (https=)
JP2023545183A5 (https=)
JP2023545182A5 (https=)
JP2021512652A5 (https=)